Loading the procedure…
Loading the procedure…
Medicare volume, surgeons, state markets and device makers
Percutaneous ventricular assist and intra-aortic balloon pump. Main billing specialties: interventional cardiology and cardiac surgery.
Medicare fee-for-service mechanical circulatory support cases in the 37 states summed: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 9% on average (146 state-years, 2020–2024): read it as a direction with a margin.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 3 | 1,597−4.2%/yr | −4.2%/yr | 0.50.8× | 0% | 1,700 in 2030+1%/yr |
| Texas | 2 | 1,476−3.6%/yr | −3.6%/yr | 0.71.2× | 0% | 2,210 in 2030+6.9%/yr |
| Florida | 5 | 1,323−3.5%/yr | −3.5%/yr | 0.61.1× | 0% | 1,380 in 2030+0.8%/yr |
| New York | 4 | 1,076−3%/yr | −3%/yr | 0.61.0× | 0% | 1,080 in 2030+0.1%/yr |
| Illinois | 6 | 983−2.7%/yr | −2.7%/yr | 0.71.3× | 0% | 910 in 2030−1.3%/yr |
| Pennsylvania | 2 | 838−4.5%/yr | −4.5%/yr | 0.61.1× | 0% | 950 in 2030+2%/yr |
| Ohio | 4 | 698−2.7%/yr | −2.7%/yr | 0.61.1× | 0% | 770 in 2030+1.6%/yr |
| Massachusetts | 3 | 596−1.7%/yr | −1.7%/yr | 0.61.1× | 0% | 560 in 2030−0.9%/yr |
| North Carolina | 1 | 534−5.9%/yr | −5.9%/yr | 0.51.0× | 0% | 550 in 2030+0.4%/yr |
| Michigan | 1 | 533−7.6%/yr | −7.6%/yr | 0.61.1× | 0% | 590 in 2030+1.8%/yr |
| New Jersey | 1 | 507+0.1%/yr | +0.1%/yr | 0.50.9× | 0% | 870 in 2030+9.4%/yr |
| Tennessee | 2 | 492−1.4%/yr | −1.4%/yr | 0.71.2× | 0% | 420 in 2030−2.5%/yr |
| Missouri | 2 | 453−5.2%/yr | −5.2%/yr | 0.71.3× | 0% | 390 in 2030−2.4%/yr |
| Indiana | 0 | 434−5.5%/yr | −5.5%/yr | 0.61.1× | 0% | 370 in 2030−2.6%/yr |
| Washington | 3 | 433−0.5%/yr | −0.5%/yr | 0.61.0× | 0% | 440 in 2030+0.2%/yr |
| Georgia | 0 | 422−6.1%/yr | −6.1%/yr | 0.50.9× | 0% | 500 in 2030+3%/yr |
| Arizona | 2 | 409−4.1%/yr | −4.1%/yr | 0.61.0× | 0% | 400 in 2030−0.5%/yr |
| Virginia | 1 | 392−3.6%/yr | −3.6%/yr | 0.40.7× | 0% | 450 in 2030+2.2%/yr |
| Maryland | 5 | 360−2%/yr | −2%/yr | 0.40.7× | 0% | 350 in 2030−0.6%/yr |
| Minnesota | 1 | 304−3.4%/yr | −3.4%/yr | 0.71.2× | 0% | 490 in 2030+8.1%/yr |
| Wisconsin | 0 | 301−5.6%/yr | −5.6%/yr | 0.50.9× | 0% | 300 in 2030−0.3%/yr |
| Louisiana | 0 | 290−8.2%/yr | −8.2%/yr | 0.71.3× | 0% | 300 in 2030+0.7%/yr |
| Kentucky | 0 | 264−6.4%/yr | −6.4%/yr | 0.61.0× | 0% | 220 in 2030−2.9%/yr |
| South Carolina | 0 | 256−4.4%/yr | −4.4%/yr | 0.40.7× | 0% | 300 in 2030+2.7%/yr |
| Alabama | 1 | 254−13%/yr | −13%/yr | 0.61.0× | 0% | 240 in 2030−1.3%/yr |
| Arkansas | 0 | 234−12%/yr | −12%/yr | 0.61.1× | 0% | 250 in 2030+1.1%/yr |
| Oklahoma | 0 | 231−9.9%/yr | −9.9%/yr | 0.50.8× | 0% | 240 in 2030+0.7%/yr |
| Iowa | 1 | 200−9.7%/yr | −9.7%/yr | 0.50.8× | 0% | 130 in 2030−7%/yr |
| Kansas | 1 | 186+0.2%/yr | +0.2%/yr | 0.50.8× | 0% | 360 in 2030+11%/yr |
| Mississippi | 0 | 161−10%/yr | −10%/yr | 0.40.8× | 0% | 180 in 2030+1.9%/yr |
| Colorado | 0 | 158−8.8%/yr | −8.8%/yr | 0.30.6× | 0% | 190 in 2030+3.2%/yr |
| Nebraska | 0 | 154−1.7%/yr | −1.7%/yr | 0.61.0× | 0% | 460 in 2030+20%/yr |
| Oregon | 0 | 153−4.9%/yr | −4.9%/yr | 0.40.6× | 0% | 280 in 2030+11%/yr |
| Connecticut | 1 | 152−4.1%/yr | −4.1%/yr | 0.50.8× | 0% | 40 in 2030−18%/yr |
| New Hampshire | 2 | 133+3.3%/yr | +3.3%/yr | 0.61.0× | 0% | 120 in 2030−1.2%/yr |
| New Mexico | 2 | 123−0.2%/yr | −0.2%/yr | 0.50.9× | 0% | 80 in 2030−6.1%/yr |
| Nevada | 0 | 118−7.9%/yr | −7.9%/yr | 0.40.7× | 0% | 200 in 2030+9.6%/yr |
Professional codes (what the surgeon bills): CPT 33990, 33991, 33995, 33967, 33970; the hospital bills MS-DRG 268, 269.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed, summed over the states listed: states MedaRep covers where the procedure tops 100 Medicare cases a year. All Medicare adds Medicare Advantage patients at each state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. How the numbers are made · Data sources
In the last 10 years FDA made 438 decisions (510(k) clearances, De Novo grants, PMA approvals and supplements) under this category’s product codes, held by 6 companies. The most active:
| Company | Decisions, 10 years |
|---|---|
| Abbott | 228 |
| Medtronic | 144 |
| Berlin Heart | 55 |
| Arrow International | 7 |
| Datascope | 3 |
| Arrow International Teleflex | 1 |
Product codes: DSP (system, balloon, intra-aortic and control), DSQ (ventricular (assist) bypass). A company whose devices for this procedure are filed under other codes is not counted, and a PMA supplement counts as a decision of its own. Applicants are rolled up to their parent company.
The competitive landscape: each company scored on innovation pace, recall and report signals, commercial momentum and financial capacity.
The 10 busiest do 100% of the cases CMS names in California; 3 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Procedure | Surgeons | Medicare FFS | Growth since 2019 | Forecast |
|---|---|---|---|---|
| Coronary intervention (PCI) | 5,056 | 218,309−6.5%/yr | −6.5%/yr | 236,300 in 2030+1.3%/yr |
| Structural heart (TAVR, TEER) | 2,849 | 63,491+3.8%/yr | +3.8%/yr | 90,800 in 2030+6.2%/yr |
| PFO & septal closure | 10 | 1,097+2.2%/yr | +2.2%/yr | 1,130 in 2030+0.5%/yr |
Every procedure · Markets by state · Device companies · Compare two states
In 2025, 5 companies reported engagement with surgeons in the covered states worth $368K in consulting, speaking, meals and travel tied to these products, about $6,574 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 48 clearances and approvals in the category, 7 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the state rankings. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.